Towards New Therapies for Parkinson's Disease / / edited by David I Finkelstein.
Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinso...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Croatia : : IntechOpen,, 2011. |
Year of Publication: | 2011 |
Language: | English |
Physical Description: | 1 online resource (410 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
LEADER | 00885nam a2200277 i 4500 | ||
---|---|---|---|
001 | 993547431304498 | ||
005 | 20221010201200.0 | ||
006 | m o d | ||
007 | cr ||||||||||| | ||
008 | 221010s2011 ci o 000 0 eng d | ||
020 | |a 953-51-6545-3 | ||
035 | |a (CKB)3230000000077137 | ||
035 | |a (NjHacI)993230000000077137 | ||
035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/65253 | ||
035 | |a (EXLCZ)993230000000077137 | ||
040 | |a NjHacI |b eng |e rda |c NjHacl | ||
041 | 0 | |a eng | |
050 | 4 | |a R742.5 |b .T693 2011 | |
082 | 0 | 4 | |a 150 |2 23 |
100 | 1 | |a Finkelstein, David I. |4 edt | |
245 | 0 | 0 | |a Towards New Therapies for Parkinson's Disease / |c edited by David I Finkelstein. |
260 | |b IntechOpen |c 2011 | ||
264 | 1 | |a Croatia : |b IntechOpen, |c 2011. | |
300 | |a 1 online resource (410 pages) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
588 | |a Description based on publisher supplied metadata and other sources. | ||
520 | |a Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies. | ||
546 | |a English | ||
650 | 0 | |a Psychology. | |
653 | |a Physiological & neuro-psychology, biopsychology | ||
776 | |z 953-307-463-9 | ||
700 | 1 | |a Finkelstein, David I, |e editor. | |
906 | |a BOOK | ||
ADM | |b 2023-02-22 19:44:36 Europe/Vienna |f system |c marc21 |a 2012-12-09 08:17:33 Europe/Vienna |g false | ||
AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338571940004498&Force_direct=true |Z 5338571940004498 |b Available |8 5338571940004498 |